Obesity study: Empagliflozin
Official title The Effect of SGLT2 Inhibition on Adipose Inflammation and Endothelial Function
ClinicalTrials.gov ID: NCT05972564
What this study is testing
What is Empagliflozin 25 MG?
This is an investigational medicine being studied to see if it can help with obesity-related inflammation. It is designed to block a protein in the kidneys that reabsorbs sugar, causing the body to remove extra sugar through urine.
Also referred to as Jardiance.
Plain-language explanation of the investigational treatment. It is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- This study aims to find out if empagliflozin can lower chronic inflammation in body fat and how this inflammation affects heart health.
- Who it's for
- The study is looking for adults who have obesity or metabolic syndrome.
- What's involved
- Participants will take empagliflozin or a placebo and undergo tests to measure inflammation in fat tissue and how well blood vessels are working.
- Time commitment
- The source text does not specify the total duration or the number of required visits.
- Phase 2: a mid-size study of how well it works
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Systolic blood pressure ≥ 130 mmHg or diastolic blood pressure ≥ 85 mmg Hg or treatment with anti-hypertensive medications for minimum of 1 month
- Triglycerides ≥ 150 mg/dL or treatment with a triglyceride-targeted medication (fenofibrate, gemfibrozil, niacin, high dose omega-3 fatty acids)
- High-density lipoprotein (HDL) \< 40 mg/dL in males or \< 50 mg/dL in females
- Fasting blood glucose ≥ 100mg/dL or treatment with glucose-lowering medications
- Waist circumference ≥ 102 cm in males or ≥ 88cm in females 3. BMI ≥ 35 kg/M2 4. The ability to provide informed consent
You likely can't join if
- 6\. Type 1 diabetes. 7. Poorly controlled type 2 diabetes as defined by HbA1c ≥ 9%. 8.
- 9\. Treatment with a glucagon-like peptide-1 receptor agonist or co-agonist in the last 3 months.
- 10\. Treatment with an SGLT2 inhibitor in the last 3 months. 11. Pregnancy or breast-feeding.
- 12\. Cardiovascular disease such as myocardial infarction within six months prior to enrollment, presence of angina pectoris, significant arrhythmia...
- 28\. Uncircumcised men or men with history of balanitis 29. History of urinary incontinence 30.
The study team makes the final eligibility decision.
Where it is enrolling
- Nashville, Tennessee, United States
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part, but confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
This study is enrolling now at Nashville, Tennessee, United States. Enter your location above to see the nearest enrolling site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool that is independent of the study sponsor. Details come from ClinicalTrials.gov. The study team decides eligibility, and your own doctor gives medical advice.